Royal Bank of Scotland Group Plc. (RBS) stock surged 5.88 percent to $7.56 in pre-market trading. European banking stock gained Friday on expectation that central banks around the world would coordinate to announce stimulus measures to rejuvenate the global economic growth.
Nokia Corp. (NOK) stock advanced 3.83 percent to $2.44 in pre-market trading. The company stock slumped more than 15 percent Thursday after the Finland-based cell phone manufacturer announced that it planned to cut 10,000 jobs globally as part of its revamping measures. The company also said that it would shut down production and research sites in Finland, Germany and Canada.
Navistar International Corp. (NAV) stock gained 2.52 percent to $28.53 in pre-market trading. Hedge fund MHR Fund Management LLC reported a 13.6 percent stake in the company in a regulatory filing Friday. Earlier this week, analysts at JPMorgan upgraded shares of NAV to neutral rating from underweight rating with a price target of $30.
Sohu.com (SOHU) stock advanced 2.14 percent to $44.00 in pre-market trading. The stock has a 52-week low of $41.18, a 52-week high of $90.37 and $1.64 billion in market capitalization.
Facebook Inc. (FB) stock advanced 1.10 percent to $28.60 in pre-market trading. The social network site is set to file a motion to consolidate all the shareholder lawsuits against the company, providing some perspective on Nasdaq's role on listing day and the effect its actions had on the stock's trading activity, the New York Times has reported citing a person with knowledge of the matter.
JPMorgan Chase & Co. (JPM) stock advanced 1.13 percent to $35.04 in pre-market trading. The stock has a 52-week low of $27.85, a 52-week high of $46.49 and $131.90 billion in market capitalization.
Alcoa Inc. (AA) stock advanced 1.04 percent to $8.74 in pre-market trading. The stock has a 52-week low of $8.21, a 52-week high of $16.60 and $9.23 billion in market capitalization.
GlaxoSmithKline plc. (GSK) stock declined 1.21 percent to $44.76 in pre-market trading. The company announced Thursday that the U.S. Food and Drug Administration (FDA) had approved the vaccine MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine).